US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

Biotech Co. Inflated Gene Therapy Prospects, Investors Claim

By Rui Johnson Petri · March 29, 2024, 12:52 PM EDT

Massachusetts-based biotechnology company Bluebird Bio Inc. misled investors by understating the safety concerns of a gene therapy for sickle cell, causing damages when stock prices dropped, according to a proposed class...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Gill v. bluebird bio, Inc. et al

Case Number

1:24-cv-10803

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

March 28, 2024

Featured Stories

Healthcare Deals This Week: Merck, Novartis And More No Photo Available

Yeji Jesse Lee

It was deal after deal this past week, as Big Pharma continued to scoop up companies.

What To Know As Sen. Cassidy Proposes Changes To 340B No Photo Available

Mark Payne

Newly introduced Senate legislation could radically change the scope of the 340B drug discount program, including by altering how prov... (more story)

Remedies, Not Suits: How FTC Approaches Health Mergers No Photo Available

Yeji Jesse Lee

The Federal Trade Commission has not sued over any healthcare provider mergers since President Donald Trump's return to the White Hous... (more story)